ATE172304T1 - Alpha b crystallin zur verwendung in diagnose und therapie von autoimmunkrankheiten, besonders multipler skerose - Google Patents

Alpha b crystallin zur verwendung in diagnose und therapie von autoimmunkrankheiten, besonders multipler skerose

Info

Publication number
ATE172304T1
ATE172304T1 AT95920305T AT95920305T ATE172304T1 AT E172304 T1 ATE172304 T1 AT E172304T1 AT 95920305 T AT95920305 T AT 95920305T AT 95920305 T AT95920305 T AT 95920305T AT E172304 T1 ATE172304 T1 AT E172304T1
Authority
AT
Austria
Prior art keywords
alpha
crystallin
multiple sclerosis
diagnoses
therapy
Prior art date
Application number
AT95920305T
Other languages
English (en)
Inventor
Noort Johannes M Van
Sechel Arianne C Van
Mustapha El Ouagmiri
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tno filed Critical Tno
Application granted granted Critical
Publication of ATE172304T1 publication Critical patent/ATE172304T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95920305T 1994-06-09 1995-06-08 Alpha b crystallin zur verwendung in diagnose und therapie von autoimmunkrankheiten, besonders multipler skerose ATE172304T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94201653 1994-06-09

Publications (1)

Publication Number Publication Date
ATE172304T1 true ATE172304T1 (de) 1998-10-15

Family

ID=8216937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95920305T ATE172304T1 (de) 1994-06-09 1995-06-08 Alpha b crystallin zur verwendung in diagnose und therapie von autoimmunkrankheiten, besonders multipler skerose

Country Status (10)

Country Link
US (1) US20100291119A9 (de)
EP (1) EP0764273B1 (de)
JP (1) JP3558347B2 (de)
AT (1) ATE172304T1 (de)
AU (1) AU696637B2 (de)
CA (1) CA2192468A1 (de)
DE (1) DE69505376T2 (de)
DK (1) DK0764273T3 (de)
ES (1) ES2125618T3 (de)
WO (1) WO1995033997A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT77047A (hu) * 1994-10-25 1998-03-02 Immulogic Pharmaceutical Corporation Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
EP1409709A2 (de) 2000-05-03 2004-04-21 Expressive Constructs, Inc. Verfahren zur verbesserung der protein-stabilität und -löslichkeit
EP1288226A1 (de) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modifizierung der Geneexpression der Mitglieder von "Toll"-ähnlicher Rezeptorfamilie zur Beeinflussung der Neurodegeneration und der Neuroprotektion im menschlichen Zentralnervensystem
EP1624886A2 (de) * 2003-05-12 2006-02-15 Expressive Constructs, Inc. Verfahren zur erhöhung der zell- und gewebevariabilität
US8771689B2 (en) 2006-12-11 2014-07-08 The Board Of Trustees Of The Leland Stanford Junior University Alpha B-crystallin as a therapy for ischemia or inflammation
AU2007333600A1 (en) 2006-12-11 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Alpha B-crystallin as a therapy for inflammation
EP2593088B1 (de) 2010-07-16 2015-01-07 Delta Crystallon B.V. Mikropartikel mit einem kleinen hitzeschockprotein
US10034915B2 (en) 2011-06-23 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
WO2014200345A1 (en) 2013-06-14 2014-12-18 Delta Crystallon B.V. Method for antigen-specific tolerance induction in humans using the small heat shock protein alpha b-crystallin.
WO2014200346A1 (en) 2013-06-14 2014-12-18 Delta Crystallon B.V. Quantification of alpha b-crystallin

Also Published As

Publication number Publication date
AU696637B2 (en) 1998-09-17
US20100291119A9 (en) 2010-11-18
WO1995033997A1 (en) 1995-12-14
ES2125618T3 (es) 1999-03-01
DK0764273T3 (da) 1999-06-23
JPH10501888A (ja) 1998-02-17
EP0764273A1 (de) 1997-03-26
JP3558347B2 (ja) 2004-08-25
CA2192468A1 (en) 1995-12-14
DE69505376D1 (de) 1998-11-19
EP0764273B1 (de) 1998-10-14
DE69505376T2 (de) 1999-04-08
AU2579995A (en) 1996-01-04
US20050013824A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
DE69729473D1 (de) Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
DE69532829D1 (de) Vorrichtung zur benutzung mit einem chirurgischen navigationssystem
ATE132269T1 (de) Verfahren zur diagnose chronischer niedriger rückenschmerzen und nackenschmerzen
DE69233723D1 (de) Verwendung von Proteinkinasen zur Diagnose und Behandlung der Alzheimer Krankheit
ATE172304T1 (de) Alpha b crystallin zur verwendung in diagnose und therapie von autoimmunkrankheiten, besonders multipler skerose
DE69510336D1 (de) Verfahren zur diagnose von praeklampsie
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
DE69310281D1 (de) Medizinisches Diagnosegerät zur Erkennung von Erkrankungen des Gehirns
DE69331813T4 (de) Verfahren zur Detektion und Behandlung von Individuen mit abnormal hla-a2/tyrosinase-peptidantigenen exprimierenden Zellen
FI933291A0 (fi) Foerfarande foer paovisning av anti-rna-antikroppar
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
ATE86633T1 (de) Snrnp-a-antigen und fragmente davon.
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE69734890D1 (de) Rdgb-proteine
ATE300554T1 (de) Bindegewebe-wachstumsfaktor 3.
Bano et al. Nerve Conductin Velocity & Amplitude of Action Potential in Sensory Peripheral Nerves of Upper & Lower Limbs in Normal Subjects
ATE316657T1 (de) Diagnostische und therapeutische verwendung des caps
Walton The science of clinical neurology
FI924328A (fi) Laite sydämen ja hermoston muodostamien biosähköisten lähteiden mittaamiseksi yhdistämällä niiden biosähköisen toiminnan synnyttämän sähköisen ja magneettisen kentän mittauksista saatava informaatio
ATE365175T1 (de) Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee